June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Changes in antibodies from glaucoma patients lead to changes in apoptosis pathways of neuroretinal cells
Author Affiliations & Notes
  • Katharina Bell
    Experimental Ophthalmology, Medical Center Univesity of Mainz, Mainz, Germany
  • Corina Wilding
    Experimental Ophthalmology, Medical Center Univesity of Mainz, Mainz, Germany
  • Sebastian Funke
    Experimental Ophthalmology, Medical Center Univesity of Mainz, Mainz, Germany
  • Norbert Pfeiffer
    Experimental Ophthalmology, Medical Center Univesity of Mainz, Mainz, Germany
  • Franz Grus
    Experimental Ophthalmology, Medical Center Univesity of Mainz, Mainz, Germany
  • Footnotes
    Commercial Relationships Katharina Bell, None; Corina Wilding, None; Sebastian Funke, None; Norbert Pfeiffer, Sensimed AG (F), Sensimed AG (R), MSD (F), MSD (R), Alcon (F), Allergan (F), Novartis (F), Novartis (R), Bayer (F), Heidelberg Engineering (F), Bausch&Lomb (F), Boehringer-Ingelheim (F), Carl Zeiss Meditech (F), Chibret (F), Nidek (F), Pfizer (F), Santen (F), Santen (R), Topcon (F), Ivantis Inc (F), Ivantis Inc (R); Franz Grus, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1605. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Katharina Bell, Corina Wilding, Sebastian Funke, Norbert Pfeiffer, Franz Grus; Changes in antibodies from glaucoma patients lead to changes in apoptosis pathways of neuroretinal cells. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1605.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Glaucoma is a neurodegenerative disease leading to apoptosis of retinal ganglion cells (rgc). Previous studies have been able to show an autoimmune component such as changes of autoantibody reactions in the serum. Studies also can demonstrate a significant effect of the serum of glaucoma patients on neuroretinal cells in vitro. Aim of this study was to analyze the effect of antibodies (Abs) from glaucoma patients on rgc in more detail.

Methods: RGC5 cells were incubated with 5% FBS and 5% serum from healthy subjects, POAG patients or with 5% FBS plus the equivalent amount of Abs from glaucoma patients for 48h. Abs were isolated from the serum with protein G spin kit. Thereafter, the protein profiles of the cells were measured with LC-ESI-MSMS. Quantification was performed with PSP, an in-house software and pathway analysis with Ingenuity software.

Results: 1694 proteins were identified successfully, of which 198 were significantly differently regulated (< - 4 fold or > 4 fold difference) in cells incubated with POAG serum and 82 in cells incubated with POAG Abs. 56% of the proteins changed in cells incubated with POAG Abs were regulated in the same significant way in cells incubated with POAG serum, 34% were regulated in the same manner and only 6% of the proteins were regulated significantly differently. Pathway analysis showed that the proteins changed in the cells incubated with POAG Abs were involved in cell regulatory pathways e.g. GAS2 involved in cell shrinkage and blebbing or BAK, involved in the mitochondrial apoptosis pathway.

Conclusions: The antibodies of glaucoma patients have significant effects on regulatory pathways in neuroretinal cells. Furthermore 90% of the changes seen in Ab incubated cells can be in cells incubated with glaucoma serum. The changes of natural autoantibodies of patients therefore could lead to a loss of protective autoimmunity and to a higher vulnerability of the cells towards external stress factors such as an elevated pressure

Keywords: 663 proteomics  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×